Your browser doesn't support javascript.
loading
A postzygotic de novo NCDN mutation identified in a sporadic FTLD patient results in neurochondrin haploinsufficiency and altered FUS granule dynamics.
Nicolas, Gaël; Sévigny, Myriam; Lecoquierre, François; Marguet, Florent; Deschênes, Andréanne; Del Pelaez, Maria Carment; Feuillette, Sébastien; Audebrand, Anaïs; Lecourtois, Magalie; Rousseau, Stéphane; Richard, Anne-Claire; Cassinari, Kévin; Deramecourt, Vincent; Duyckaerts, Charles; Boland, Anne; Deleuze, Jean-François; Meyer, Vincent; Clarimon Echavarria, Jordi; Gelpi, Ellen; Akiyama, Haruhiko; Hasegawa, Masato; Kawakami, Ito; Wong, Tsz H; Van Rooij, Jeroen G J; Van Swieten, John C; Campion, Dominique; Dutchak, Paul A; Wallon, David; Lavoie-Cardinal, Flavie; Laquerrière, Annie; Rovelet-Lecrux, Anne; Sephton, Chantelle F.
Affiliation
  • Nicolas G; Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
  • Sévigny M; Department of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6.
  • Lecoquierre F; CERVO Brain Research Centre, Laval University, Quebec City, QC, Canada, 2601, chemin de la Canardière, G1J 2G3.
  • Marguet F; Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
  • Deschênes A; Inserm U1245 and CHU Rouen, Department of Pathology, Normandie University, UNIROUEN, F-76000, Rouen, France.
  • Del Pelaez MC; Department of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6.
  • Feuillette S; CERVO Brain Research Centre, Laval University, Quebec City, QC, Canada, 2601, chemin de la Canardière, G1J 2G3.
  • Audebrand A; Department of Biochemistry, Microbiology and Bioinformatics, Laval University, Quebec City, QC, Canada.
  • Lecourtois M; Department of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6.
  • Rousseau S; CERVO Brain Research Centre, Laval University, Quebec City, QC, Canada, 2601, chemin de la Canardière, G1J 2G3.
  • Richard AC; Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
  • Cassinari K; Department of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6.
  • Deramecourt V; CERVO Brain Research Centre, Laval University, Quebec City, QC, Canada, 2601, chemin de la Canardière, G1J 2G3.
  • Duyckaerts C; Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
  • Boland A; Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
  • Deleuze JF; Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
  • Meyer V; Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
  • Clarimon Echavarria J; Lille Neuroscience and Cognition (Inserm UMRS1172) Alzheimer and Tauopathies, Laboratory of Excellence Distalz (Development of Innovative Strategies for a Transdisciplinary Approach to ALZheimer's Disease), University of Lille, CHU Lille, Lille, France.
  • Gelpi E; Department of Neuropathology, University of Lille, CHU Lille, Lille, France.
  • Akiyama H; INSERM, CNRS U1127, Institut du Cerveau, Sorbonne Université, ICM, Paris, France.
  • Hasegawa M; Laboratoire de Neuropathologie R. Escourolle, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France.
  • Kawakami I; CEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France.
  • Wong TH; CEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France.
  • Van Rooij JGJ; CEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France.
  • Van Swieten JC; Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Campion D; Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  • Dutchak PA; Neurological Tissue Bank of the Biobank-Hospital Clinic-IDIBAPS, Barcelona, Spain.
  • Wallon D; Division of Neuropathology, Department of Neurology, Medical University of Vienna, Vienna, Austria.
  • Lavoie-Cardinal F; Dementia Research Project, Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Setagaya City, Japan.
  • Laquerrière A; Dementia Research Project, Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Setagaya City, Japan.
  • Rovelet-Lecrux A; Dementia Research Project, Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Setagaya City, Japan.
  • Sephton CF; Department of Neurology and Alzheimer Center, Erasmus Medical Center, Rotterdam, The Netherlands.
Acta Neuropathol Commun ; 10(1): 20, 2022 02 12.
Article in En | MEDLINE | ID: mdl-35151370
Frontotemporal dementia (FTD) is a heterogeneous clinical disorder characterized by progressive abnormalities in behavior, executive functions, personality, language and/or motricity. A neuropathological subtype of FTD, frontotemporal lobar degeneration (FTLD)-FET, is characterized by protein aggregates consisting of the RNA-binding protein fused in sarcoma (FUS). The cause of FTLD-FET is not well understood and there is a lack of genetic evidence to aid in the investigation of mechanisms of the disease. The goal of this study was to identify genetic variants contributing to FTLD-FET and to investigate their effects on FUS pathology. We performed whole-exome sequencing on a 50-year-old FTLD patient with ubiquitin and FUS-positive neuronal inclusions and unaffected parents, and identified a de novo postzygotic nonsense variant in the NCDN gene encoding Neurochondrin (NCDN), NM_014284.3:c.1206G > A, p.(Trp402*). The variant was associated with a ~ 31% reduction in full-length protein levels in the patient's brain, suggesting that this mutation leads to NCDN haploinsufficiency. We examined the effects of NCDN haploinsufficiency on FUS and found that depleting primary cortical neurons of NCDN causes a reduction in the total number of FUS-positive cytoplasmic granules. Moreover, we found that these granules were significantly larger and more highly enriched with FUS. We then examined the effects of a loss of FUS function on NCDN in neurons and found that depleting cells of FUS leads to a decrease in NCDN protein and mRNA levels. Our study identifies the NCDN protein as a likely contributor of FTLD-FET pathophysiology. Moreover, we provide evidence for a negative feedback loop of toxicity between NCDN and FUS, where loss of NCDN alters FUS cytoplasmic dynamics, which in turn has an impact on NCDN expression.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Brain / RNA-Binding Protein FUS / Frontotemporal Dementia / Nerve Tissue Proteins / Neurons Type of study: Prognostic_studies Limits: Female / Humans / Middle aged Language: En Journal: Acta Neuropathol Commun Year: 2022 Type: Article Affiliation country: France

Full text: 1 Database: MEDLINE Main subject: Brain / RNA-Binding Protein FUS / Frontotemporal Dementia / Nerve Tissue Proteins / Neurons Type of study: Prognostic_studies Limits: Female / Humans / Middle aged Language: En Journal: Acta Neuropathol Commun Year: 2022 Type: Article Affiliation country: France